By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.

RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, ...

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...

Roche has released positive topline one-year findings from a Phase IV trial of Vabysmo (faricimab) to treat diabetic macular ...

A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African ...

Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...

Swiss pharma giant Roche (ROG: SIX) on Friday released positive top-line one-year results from the open-label, single-arm ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

Roche stock jumped Wednesday after the pharma giant reported light third-quarter sales but kept its 2024 outlook.

Roche (RHHBY) announced positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo ...

The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic ...